{"nctId":"NCT03363854","briefTitle":"Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3","startDateStruct":{"date":"2018-02-22","type":"ACTUAL"},"conditions":["Atopic Dermatitis"],"count":380,"armGroups":[{"label":"Tralokinumab(initial)responders-> Tralokinumab(continuation A)","type":"EXPERIMENTAL","interventionNames":["Drug: Tralokinumab"]},{"label":"Tralokinumab(initial)responders-> Tralokinumab(continuation B)","type":"EXPERIMENTAL","interventionNames":["Drug: Tralokinumab"]},{"label":"Tralokinumab(initial)non-respon-> Tralokinumab(continuation A)","type":"EXPERIMENTAL","interventionNames":["Drug: Tralokinumab"]},{"label":"Placebo (initial)non-respon-> Tralokinumab(continuation A)","type":"EXPERIMENTAL","interventionNames":["Drug: Tralokinumab","Drug: Placebo"]},{"label":"Placebo(initial)responders-> Placebo(continuation A)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Tralokinumab","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age 18 and above.\n* Diagnosis of AD as defined by the Hanifin and Rajka (1980) criteria for AD.\n* History of AD for ≥1 year.\n* Subjects who have a recent history of inadequate response to treatment with topical medications.\n* AD involvement of ≥10% body surface area at screening and baseline.\n* Stable dose of emollient twice daily (or more, as needed) for at least 14 days before randomisation.\n\nExclusion Criteria:\n\n* Subjects for whom TCS are medically inadvisable e.g., due to important side effects or safety risks in the opinion of the investigator.\n* Active dermatologic conditions that may confound the diagnosis of AD.\n* Use of tanning beds or phototherapy within 6 weeks prior to randomisation.\n* Treatment with systemic immunosuppressive/immunomodulating drugs and/or systemic corticosteroid within 4 weeks prior to randomisation.\n* Treatment with TCS, topical calcineurin inhibitors (TCI), or topical phosphodiesterase 4 (PDE-4) inhibitor within 2 weeks prior to randomisation.\n* Receipt of any marketed biological therapy (i.e. immunoglobulin, anti- immunoglobulin E) including dupilumab or investigational biologic agents within 3 months or 5 half-lives, whichever is longer prior to randomisation.\n* Active skin infection within 1 week prior to randomisation.\n* Clinically significant infection within 4 weeks prior to randomisation.\n* A helminth parasitic infection within 6 months prior to the date informed consent is obtained.\n* Tuberculosis requiring treatment within the 12 months prior to screening.\n* Known primary immunodeficiency disorder.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Participants With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16","description":"IGA is used to evaluate the severity of atopic dermatitis. It is a 5-point score ranging from 0 (clear) to 4 (severe).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]}]},{"type":"PRIMARY","title":"Participants Achieving at Least 75% Reduction in Eczema Area and Severity Index (EASI) at Week 16","description":"EASI is used to evaluate the extent and severity of atopic dermatitis. It is a composite score ranging from 0 to 72 with a higher score indicating a more extensive and/or severe condition.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"141","spread":null},{"groupId":"OG001","value":"45","spread":null}]}]}]},{"type":"SECONDARY","title":"Reduction of Worst Daily Pruritus Numeric Rating Scale (NRS) (Weekly Average) of at Least 4 From Baseline to Week 16","description":"Worst Daily Pruritus NRS is used by the participant to evaluate their worst itch severity over the past 24 hours. The score ranges from 0 ('no itch') to 10 ('worst itch imaginable') on an 11-point scale.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"113","spread":null},{"groupId":"OG001","value":"43","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Scoring Atopic Dermatitis (SCORAD) From Baseline to Week 16","description":"SCORAD is used to evaluate the extent and severity of atopic dermatitis as well as subjective symptoms. The score ranges from 0 to 103 with a higher score indicating a more extensive and/or severe condition.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-37.7","spread":"1.25"},{"groupId":"OG001","value":"-26.8","spread":"1.80"}]}]}]},{"type":"SECONDARY","title":"Change in Dermatology Life Quality Index (DLQI) Score From Baseline to Week 16","description":"DLQI is used by the participant to evaluate the impact of their condition on 10 different aspects of health-related quality of life (HRQoL) over the last week. Each item is scored on a 4-point Likert scale ranging from 0 (not at all/not relevant) to 3 (very much). The total score which is the sum of the 10 items ranges from 0 to 30, with a higher score indicating a poorer HRQoL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.7","spread":"0.39"},{"groupId":"OG001","value":"-8.8","spread":"0.56"}]}]}]},{"type":"SECONDARY","title":"Frequency of Anti-drug Antibodies (ADA)","description":"Presence of ADA from Week 0 to Week 32 was measured. Data were reported in the following categories: positive (presence of ADA at baseline and/or presence of ADA at at least 1 post-baseline assessment), perishing (presence of ADA at baseline and absence of ADA at all post-baseline assessments), negative (absence of ADA at all assessments), no post-baseline ADA assessment. Perishing ADAs were not assessed in the continuation treatment period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"246","spread":null},{"groupId":"OG001","value":"123","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"2","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"3","spread":null},{"groupId":"OG006","value":"2","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"66","spread":null},{"groupId":"OG003","value":"63","spread":null},{"groupId":"OG004","value":"92","spread":null},{"groupId":"OG005","value":"74","spread":null},{"groupId":"OG006","value":"37","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null},{"groupId":"OG005","value":"0","spread":null},{"groupId":"OG006","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Amount of Topical Corticosteroid (TCS) Used Through Week 16 Assuming no TCS Used From the Non-returned Tubes","description":"Assessed as the amount of TCS weighed from previous visits, assuming no TCS was used from the non-returned tubes. Measurements were collected as TCS weight (g) between the visits.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.3","spread":"2.45"},{"groupId":"OG001","value":"32.8","spread":"3.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.7","spread":"1.86"},{"groupId":"OG001","value":"26.6","spread":"2.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.5","spread":"1.72"},{"groupId":"OG001","value":"23.2","spread":"2.46"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.0","spread":"2.04"},{"groupId":"OG001","value":"24.3","spread":"2.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.8","spread":"1.66"},{"groupId":"OG001","value":"23.9","spread":"2.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.6","spread":"1.38"},{"groupId":"OG001","value":"19.6","spread":"2.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.7","spread":"1.61"},{"groupId":"OG001","value":"23.0","spread":"2.33"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.6","spread":"1.57"},{"groupId":"OG001","value":"20.2","spread":"2.27"}]}]}]},{"type":"SECONDARY","title":"Amount of Topical Corticosteroid (TCS) Used Through Week 16 Assuming All TCS Used From the Non-returned Tubes","description":"Assessed as the amount of TCS weighed from previous visits, assuming all TCS was used from the non-returned tubes. Measurements were collected as TCS weight (g) between the visits.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.1","spread":"3.22"},{"groupId":"OG001","value":"40.1","spread":"4.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.4","spread":"3.00"},{"groupId":"OG001","value":"31.3","spread":"4.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.2","spread":"2.89"},{"groupId":"OG001","value":"30.6","spread":"4.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.2","spread":"2.89"},{"groupId":"OG001","value":"30.0","spread":"4.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.5","spread":"2.61"},{"groupId":"OG001","value":"26.9","spread":"3.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.9","spread":"2.23"},{"groupId":"OG001","value":"23.1","spread":"3.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.6","spread":"2.22"},{"groupId":"OG001","value":"25.5","spread":"3.23"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.3","spread":"2.26"},{"groupId":"OG001","value":"24.8","spread":"3.27"}]}]}]},{"type":"SECONDARY","title":"Number of Atopic Dermatitis Flares Through Week 16","description":"Assessed as appearance of new flares since previous visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"119","spread":null},{"groupId":"OG001","value":"75","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Days Without Topical Treatment Use From Baseline to Week 16","description":"Participants assessed their use of topical treatment over the past 24 hours using a response scale ('yes', 'no'). Measurements of number of days per week were used in the analysis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":"0.17"},{"groupId":"OG001","value":"2.5","spread":"0.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":"0.18"},{"groupId":"OG001","value":"2.6","spread":"0.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"0.17"},{"groupId":"OG001","value":"2.7","spread":"0.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":"0.17"},{"groupId":"OG001","value":"2.7","spread":"0.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"0.17"},{"groupId":"OG001","value":"2.7","spread":"0.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":"0.18"},{"groupId":"OG001","value":"2.8","spread":"0.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":"0.17"},{"groupId":"OG001","value":"2.7","spread":"0.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":"0.18"},{"groupId":"OG001","value":"3.0","spread":"0.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":"0.17"},{"groupId":"OG001","value":"2.6","spread":"0.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"0.17"},{"groupId":"OG001","value":"2.7","spread":"0.25"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":"0.18"},{"groupId":"OG001","value":"2.7","spread":"0.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"0.18"},{"groupId":"OG001","value":"2.7","spread":"0.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":"0.18"},{"groupId":"OG001","value":"2.7","spread":"0.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":"0.18"},{"groupId":"OG001","value":"2.6","spread":"0.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":"0.18"},{"groupId":"OG001","value":"2.8","spread":"0.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"0.19"},{"groupId":"OG001","value":"3.0","spread":"0.27"}]}]}]},{"type":"SECONDARY","title":"Participants Achieving at Least 50% Reduction in Eczema Area and Severity Index (EASI) at Week 16","description":"EASI is used to evaluate the extent and severity of atopic dermatitis. It is a composite score ranging from 0 to 72 with a higher score indicating a more extensive and/or severe condition.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"200","spread":null},{"groupId":"OG001","value":"73","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants Achieving at Least 90% Reduction in Eczema Area and Severity Index (EASI) at Week 16","description":"EASI is used to evaluate the extent and severity of atopic dermatitis. It is a composite score ranging from 0 to 72 with a higher score indicating a more extensive and/or severe condition.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83","spread":null},{"groupId":"OG001","value":"27","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 16 in Eczema Area and Severity Index (EASI) Score","description":"EASI is used to evaluate the extent and severity of atopic dermatitis. It is a composite score ranging from 0 to 72 with a higher score indicating a more extensive and/or severe condition.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-21.0","spread":"0.67"},{"groupId":"OG001","value":"-15.6","spread":"0.96"}]}]}]},{"type":"SECONDARY","title":"Participants Achieving at Least 50% Reduction in Scoring Atopic Dermatitis (SCORAD) at Week 16","description":"SCORAD is used to evaluate the extent and severity of atopic dermatitis as well as subjective symptoms. The score ranges from 0 to 103 with a higher score indicating a more extensive and/or severe condition.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"154","spread":null},{"groupId":"OG001","value":"48","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants Achieving at Least 75% Reduction in Scoring Atopic Dermatitis (SCORAD) at Week 16","description":"SCORAD is used to evaluate the extent and severity of atopic dermatitis as well as subjective symptoms. The score ranges from 0 to 103 with a higher score indicating a more extensive and/or severe condition.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline to Week 16 in Worst Daily Pruritus Numeric Rating Scale (NRS) (Weekly Average)","description":"Worst Daily Pruritus NRS is used by the participant to evaluate their worst itch severity over the past 24 hours. The score ranges from 0 ('no itch') to 10 ('worst itch imaginable') on an 11-point scale.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.1","spread":"0.15"},{"groupId":"OG001","value":"-2.9","spread":"0.21"}]}]}]},{"type":"SECONDARY","title":"Reduction From Baseline to Week 16 of Dermatology Life Quality Index (DLQI) of at Least 4 Points Among Participants With Baseline DLQI ≥4","description":"DLQI is used by the participant to evaluate the impact of their condition on 10 different aspects of health-related quality of life (HRQoL) over the last week. Each item is scored on a 4-point Likert scale ranging from 0 (not at all/not relevant) to 3 (very much). The total score which is the sum of the 10 items ranges from 0 to 30, with a higher score indicating a poorer HRQoL.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"207","spread":null},{"groupId":"OG001","value":"81","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 32 Among Participants With IGA Score of 0 or 1 at Week 16 After Initial Randomisation to Tralokinumab","description":"IGA is used to evaluate the severity of atopic dermatitis. It is a 5-point score ranging from 0 (clear) to 4 (severe).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"38","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants Achieving at Least 75% Reduction in Eczema Area and Severity Index (EASI) at Week 32 Among Participants Who Had Achieved at Least 75% Reduction in EASI at Week 16 After Initial Randomisation to Tralokinumab","description":"EASI is used to evaluate the extent and severity of atopic dermatitis. It is a composite score ranging from 0 to 72 with a higher score indicating a more extensive and/or severe condition.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62","spread":null},{"groupId":"OG001","value":"59","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":252},"commonTop":["Viral upper respiratory tract infection","Upper respiratory tract infection","Headache","Conjunctivitis","Dermatitis atopic"]}}}